Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04474314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04474314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 13, 2020
Completion date
May 4, 2022
Enrollment
115 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease